



Universiteit
Leiden
The Netherlands

Host-directed therapy for the treatment of tuberculosis: rewiring the host to recover control

Heemskerk, M.T.

Citation

Heemskerk, M. T. (2026, April 23). *Host-directed therapy for the treatment of tuberculosis: rewiring the host to recover control*. Retrieved from <https://hdl.handle.net/1887/4302677>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4302677>

Note: To cite this publication please use the final published version (if applicable).

Curriculum Vitae

Born in Leiden on October 19th, 1989, Maarten Thomas (Matthias) Heemskerk grew up in Katwijk aan Zee. His interest in biology started at the age of 10, when he received a microscope as a gift. Armed with microscope slides, he explored the house, the neighbourhood, as well as blood obtained with the finger prick lancet from a friend's father. This interest was grown by the beta sciences oriented profile during his VWO education. After graduating high school in 2008, he enrolled in the bachelor Life Science & Technology at Leiden and Delft. During his Bachelor internship, he took part in a research project on identifying host factors that play a role in intracellular Chikungunya virus replication. Drawn in particular to cell biology, he did his master's in Life Science & Technology at Leiden. In his first Master internship, he worked on optimizing the simultaneous isolation of various T-cell populations using MHCII-Streptamer isolation technology. His second Master internship focused on short hairpin RNAs and improving their activity and biogenesis. Eager to learn more, he started his research to attain his Ph.D. at the Department of Infectious Diseases of the Leiden University Medical Center, in 2014, even prior to having graduated. Through teamwork and collaborations, he aimed for maximizing the impact of his work of which the results are described in this thesis. In 2020, he leveraged his skills and expertise to help develop a cell therapy manufacturing process fit for decentralized production at the start-up company CellPoint. By working on preclinical development, analytical development and quality control, he helped start clinical trials for three different cell therapy products. Currently, he leads the analytical development department at Galapagos and is responsible for developing the innovative release and testing strategy required for this next generation of cell therapy production.

List of Publications

Kiliç G, Boland R*, **Heemskerk MT***, Spaink HP, Haks MC, van der Vaart M, Ottenhoff THM, Meijer AH, Saris A. *Host-directed therapy with amiodarone in preclinical models restricts mycobacterial infection and enhances autophagy*. Microbiol Spectr. 2024 Aug 6.

Boland R*, **Heemskerk MT***, Forn-Cuní G, Korbee CJ, Walburg KV, Esselink JJ, Carvalho Dos Santos C, de Waal AM, van der Hoeven DCM, van der Sar E, de Ries AS, Xie J, Spaink HP, van der Vaart M, Haks MC, Meijer AH, Ottenhoff THM. *Repurposing Tamoxifen as Potential Host-Directed Therapeutic for Tuberculosis*. mBio. 2023 Feb 28.

Heemskerk MT, Korbee CJ, Esselink JJ, Dos Santos CC, van Veen S, Gordijn IF, Vrieling F, Walburg KV, Engele CG, Dijkman K, Wilson L, Verreck FAW, Ottenhoff THM, Haks MC. *Repurposing diphenylbutylpiperidine-class antipsychotic drugs for host-directed therapy of Mycobacterium tuberculosis and Salmonella enterica infections*. Sci Rep. 2021 Oct 4.

van Doorn CLR, Schouten GK, van Veen S, Walburg KV, Esselink JJ, **Heemskerk MT**, Vrieling F, Ottenhoff THM. *Pyruvate Dehydrogenase Kinase Inhibitor Dichloroacetate Improves Host Control of Salmonella enterica Serovar Typhimurium Infection in Human Macrophages*. Front Immunol. 2021 Sep 6.

Bakkum T, **Heemskerk MT**, Bos E, Groenewold M, Oikonomou-Koppas N, Walburg KV, van Veen S, van der Lienden MJC, van Leeuwen T, Haks MC, Ottenhoff THM, Koster AJ, van Kasteren SI. *Bioorthogonal Correlative Light-Electron Microscopy of Mycobacterium tuberculosis in Macrophages Reveals the Effect of Antituberculosis Drugs on Subcellular Bacterial Distribution*. ACS Cent Sci. 2020 Nov 25.

Moreira JD, Koch BEV, van Veen S, Walburg KV, Vrieling F, Mara Pinto Dabés Guimarães T, Meijer AH, Spaink HP, Ottenhoff THM, Haks MC*, **Heemskerk MT***. *Functional Inhibition of Host Histone Deacetylases (HDACs) Enhances in vitro and in vivo Anti-mycobacterial Activity in Human Macrophages and in Zebrafish*. Front Immunol. 2020 Feb 3.

Korbee CJ*, **Heemskerk MT***, Kocev D, van Strijen E, Rabiee O, Franken KLMC, Wilson L, Savage ND, Džeroski S, Haks MC, Ottenhoff THM. *Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials*. Nat Commun. 2018 Jan 24.

Herrera-Carrillo E, Gao ZL, Harwig A, **Heemskerk MT**, Berkhout B. *The influence of the 5'-terminal nucleotide on AgoshRNA activity and biogenesis: importance of the polymerase III transcription initiation site.* Nucleic Acids Res. 2017 Apr 20.

Roex MCJ, Hageman L, **Heemskerk MT**, Veld SAJ, van Liempt E, Kester MGD, Germeroth L, Stemberger C, Falkenburg JHF, Jedema I. *The simultaneous isolation of multiple high and low frequent T-cell populations from donor peripheral blood mononuclear cells using the major histocompatibility complex I-Streptamer isolation technology.* Cytotherapy. 2018 Apr 20.

Treffers EE, Tas A, Scholte FE, Van MN, **Heemskerk MT**, de Ru AH, Snijder EJ, van Hemert MJ, van Veelen PA. *Temporal SILAC-based quantitative proteomics identifies host factors involved in chikungunya virus replication.* Proteomics. 2015 Jul 15.

* contributed equally

Acknowledgements

To say this thesis has been 'in progress' is an understatement; it has been a permanent resident of my subconscious for the past decade. Balancing the rigors of a career and the delightful, if exhausting, distraction of my children meant that the writing phase underwent a significant aging process. That it is finally finished is less a triumph of planning and more a victory of sheer stubbornness. I now need to acknowledge some of the (un)willing participants in this journey.

First, I would like to thank you, Tom. I have learned many things from you, and it was an inspiration to watch you lead the group. Your incredibly short turnaround time for providing feedback was both a blessing and a curse; despite me taking quite a bit longer, you never stopped supporting me with your saint-like patience. Annemarie, thank you for providing your expertise and support exactly when it was needed. Your involvement was instrumental in the completion of this work.

Kees, the onboarding I received from you as well as the sharing of your research has made a great difference. Your resilience was an inspiration, and I feel conflicted about beating your time to completion. Anouk, Cassandra, Mikolaj, Maria, Calinda, and Teresa, thank you for the wonderful time we had together. Your presence truly enriched my years at INZI.

Krista, we spent many years sitting next to each other, during which you provided support and advice of every possible nature. Thank you for always being there. Kimberley, Susan, Suzanne, Louis, and Anna, you made the group complete with your cheerfulness and knowledge. Thank you E5-colleagues Bep, Annelies, and Peter, for sharing both your expertise and laughter.

Tol, Maarten, Lorraine, and Jacqueline, though you were part of the "next" journey, your support while I finished this work was invaluable. Margot and Joost, thank you for the friendship and expertise you've shared the past years. It would not have been the same without you. And of course, Jeroen: since we were in the same boat, I truly appreciate you absorbing so many of those "So, when will it be ready?" questions for me. It didn't go unnoticed!

Thank you, Mayank, Isabelle, Jeroen, and Gül for all the dedication and enthusiasm you showed during your internships. Your contributions are valued. Josimar, having you over from Brazil was an amazing experience for both of us. Thank you for the great work you did and the results we got to publish; I will certainly never forget the procedure for making the best Caipirinha. This extends to Carina as well, thank you for your

contribution to the HDT work. Alexander, I very much appreciate your resilience with our complicated ABPP experiments, and Ralf, our parallel work has led to results where the sum is greater than the parts, no doubt aided by the amount of coffee, beer, and pizza we consumed. Robin, I very much appreciate your support on the 97i chapter.

Thomas, we have shared the destruction of billions of bacteria, the climbing of many boulders, and several courses of Italian. I'm very happy that we met and became friends. Emile, your perspective on life was often helpful during this journey, as were the meals and experiences we've shared. I'm glad you introduced Mo to us and I am proud to call you a friend.

Frank, besides being an amazing friend, you were of great help by always indulging me in scientific discussions. You stood by my side during the most challenging moments of this journey, from scientific hurdles to transformative life decisions.

A deep thanks to my mom and my sisters Tamara, Marjolein, Deborah, and Rosanne. Our journey as a family was an eventful one, but we made it. Your support and hugs remain as important as ever. Jan K, Jan N, Arend and Frank, thank you for being there for us. Aldo, Teresa, Francesca e Alessandro, la mia famiglia Italiana: vi ringrazio per il vostro affetto e per avermi fatto sentire a casa.

Mari, you were the most profound discovery of this PhD. What began in the lab evolved into a friendship and, inevitably, into the life we share today. Thank you for building this world with me; I am immensely grateful to you.

Iris and Roan, you are my greatest joy and the true essence of my life.